Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Change in Receivables (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Change in Receivables for 16 consecutive years, with $347839.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 489.17% year-over-year to $347839.0, compared with a TTM value of -$203643.0 through Oct 2025, up 85.71%, and an annual FY2025 reading of -$203643.0, up 86.02% over the prior year.
  • Change in Receivables was $347839.0 for Q4 2025 at Pharma-Bio Serv, up from -$675376.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $663696.0 in Q2 2023 and bottomed at -$1.6 million in Q1 2024.
  • Average Change in Receivables over 5 years is -$61504.4, with a median of $101054.5 recorded in 2024.
  • The sharpest move saw Change in Receivables surged 1358.88% in 2021, then tumbled 4389.74% in 2025.
  • Year by year, Change in Receivables stood at $471457.0 in 2021, then crashed by 143.68% to -$205939.0 in 2022, then plummeted by 580.03% to -$1.4 million in 2023, then skyrocketed by 93.62% to -$89380.0 in 2024, then soared by 489.17% to $347839.0 in 2025.
  • Business Quant data shows Change in Receivables for PBSV at $347839.0 in Q4 2025, -$675376.0 in Q3 2025, and -$62471.0 in Q2 2025.